In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Comparative effectiveness of revascularisation strategies.

Session Optimal revascularisation for patients with complex lesions or multivessel coronary artery disease

Speaker William Weintraub

Event : ESC Congress 2013

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Symposium

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two columns page  

Optimal revascularisation for patients with complex lesions or multivessel coronary artery disease

Cardiovascular Surgery

 

Dr. Weintraub presented the potential value of registries, describing the ASCERT study of almost 190,000 patients undergoing PCI (almost 80% with DES) or CABG in patients aged over 65 years.  The study (published in the NEJM 2012) reported 4.4% superior survival with CABG at 4 years.  Findings persisted across 10 subsets of patients. 

Dr. Farooq presented the importance of scoring systems to allow improved prediction of likely outcome in patients undergoing PCI or CABG.  He described the SYNTAX II Study (Lancet 2013) in identifying 8 variables which enabled prediction of survival in patients undergoing PCI or CABG. 

Dr. Girerd described the adverse impact of incomplete revascularisation on long term survival and especially in younger patients. Dr Kappetein presented the Freedom Trial in patients with diabetes where CABG had a 5.4% survival advantage at 5 years over PCI.  Similar findings were observed in the subset of patients with diabetes in the SYNTAX Trial. 

Dr. Taggart summarised the session emphasising (i) that previous RCTs of PCI versus CABG (with the exception of the SYNTAX Trial) had enrolled highly selected patients who were quite different from most CABG patients; (ii) that the survival advantage of CABG over PCI did not usually emerge until 3-5 years; (iii) the difference between appropriate and inappropriate complete revascularisation (during PCI and CABG). Finally, he emphasised the importance of interventions in individual patients being overseen by the heart team rather than by individual practitioners to ensure that patients were likely to receive the optimal intervention, whether by PCI or CABG.

References


907

SessionTitle:

Optimal revascularisation for patients with complex lesions or multivessel coronary artery disease

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are